(Q27007027)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

Therapeutic modalities in diabetic nephropathy: standard and emerging approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Lawand Saadulla

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Emaad M Abdel-Rahman

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Alaa S Awad

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

1 reference

18 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

Journal of General Internal Medicine

14 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

458-468

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

14 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Supramaximal dose of candesartan in proteinuric renal disease

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Therapeutic potential of breakers of advanced glycation end product–protein crosslinks

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

21 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

21 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Aliskiren and dual therapy in type 2 diabetes mellitus

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Glucose control and vascular complications in veterans with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

10-year follow-up of intensive glucose control in type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Diabetes, hypertension, and outcome studies: overview 2010.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effects of intensive blood-pressure control in type 2 diabetes mellitus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Avosentan for overt diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Lowering blood pressure reduces renal events in type 2 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The incidence and implications of aldosterone breakthrough

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The emerging role of angiotensin-converting enzyme-2 in the kidney

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Standards of medical care in diabetes--2007.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Enhancing the predictive value of urinary albumin for diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Differential effects of calcium antagonist subclasses on markers of nephropathy progression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Haemodynamics in microvascular complications in type 1 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Pimagedine: a novel therapy for diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Insulin resistance and its treatment by thiazolidinediones

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Angiotensin-converting enzyme inhibitors in diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Prevention of diabetic renal disease with special reference to microalbuminuria

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Defining the role of endothelins in renal pathophysiology on the basis of selective and unselective endothelin receptor antagonist studies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Liver X receptor-alpha mediates cholesterol efflux in glomerular mesangial cells

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Pancreas transplant outcomes for United States (US) and non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR) as of October 2002.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Reversal of lesions of diabetic nephropathy after pancreas transplantation

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Understanding the nature of renal disease progression

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Renal protection in diabetes: an emerging role for calcium antagonists.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Appropriate Blood Pressure Control in NIDDM (ABCD) Trial

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Autocrine role of endothelin in rat inner medullary collecting duct: inhibition of AVP-induced cAMP accumulation

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Diabetic nephropathy: Linking histology, cell biology, and genetics

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

The beneficial effects of pancreas transplant alone on diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

The effects of spironolactone on nephron function in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Beneficial impact of spironolactone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Nephrologist care and mortality in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

The timing of specialist evaluation in chronic kidney disease and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Renal protective effect of YM598, a selective endothelin type A receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Nephroprotective effect of bosentan in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Amides are novel protein modifications formed by physiological sugars

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Renal Endothelin System in Diabetes: Comparison of Angiotensin-Converting Enzyme Inhibition and Endothelin-A Antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Urinary Connective Tissue Growth Factor Excretion Correlates With Clinical Markers of Renal Disease in a Large Population of Type 1 Diabetic Patients With Diabetic Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11606-011-1912-5

Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3304033

Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD

28 November 2018

1 reference

12 December 2020

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

1 reference

12 December 2020

Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes

1 reference

12 December 2020

Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats

1 reference

12 December 2020

Urinary excretion of podocytes in patients with diabetic nephropathy

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells

1 reference

12 December 2020

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

12 December 2020

Predicting diabetic nephropathy in insulin-dependent patients

1 reference

12 December 2020

Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial

1 reference

12 December 2020

Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy

1 reference

12 December 2020

Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus

1 reference

12 December 2020

Prostaglandins, angiotension II, and proteinuria

1 reference

12 December 2020

Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients

1 reference

12 December 2020

Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?

1 reference

12 December 2020

Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients

1 reference

12 December 2020

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020

Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys

1 reference

12 December 2020

A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension

1 reference

12 December 2020

Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria

1 reference

12 December 2020

Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the Swedish national diabetes register

1 reference

12 December 2020

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group

1 reference

12 December 2020

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group

1 reference

12 December 2020

Hyperlipidemia and diabetes mellitus

1 reference

12 December 2020

Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation

1 reference

12 December 2020

Standards of medical care in diabetes

1 reference

12 December 2020

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

1 reference

12 December 2020

Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes

1 reference

12 December 2020

Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria

1 reference

12 December 2020

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

1 reference

12 December 2020

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

12 December 2020

Treatment of hypertension in adults with diabetes

1 reference

12 December 2020

Progression of chronic renal disease

1 reference

12 December 2020

Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions

1 reference

12 December 2020

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients

1 reference

12 December 2020

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

1 reference

12 December 2020

Differences Between Nisoldipine and Lisinopril on Glomerular Filtration Rates and Albuminuria in Hypertensive IDDM Patients With Diabetic Nephropathy During the First Year of Treatment

1 reference

12 December 2020

Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans

1 reference

12 December 2020

Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy

1 reference

12 December 2020

Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats

1 reference

12 December 2020

Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group

1 reference

12 December 2020

Expression of connective tissue growth factor in human renal fibrosis

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats

1 reference

12 December 2020

Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy

1 reference

12 December 2020

Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals

1 reference

12 December 2020

Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis

1 reference

12 December 2020

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

12 December 2020

10.1007/S11606-011-1912-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

14 January 2020

1045767789

0 references

OpenCitations bibliographic resource ID

1219526

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1219526

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22005942%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

PubMed publication ID

22005942

1 reference